Oral administration of ampelopsin protects against acute brain injury in rats following focal cerebral ischemia

Experimental and Therapeutic Medicine

Volumn 13, Issue 5, 2017, Pages 1725-1734

  Ye, Xiao Li ^a   Lu, Ling Qun ^b   Li, Wei ^b   Lou, Q I ^b   Guo, Hong Gang ^b   Shi, Qiao Juan ^b  

^a CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Ampelopsin; Middle cerebral artery occlusion; Neuroprotection; Pranlukast

Indexed keywords

AMPELOPSIN; CHLORAL HYDRATE; HERBACEOUS AGENT; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; PRANLUKAST; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AMPELOPSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR ASSESSMENT; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; EDEMA; ENZYME LINKED IMMUNOSPOT ASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NERVE CELL DEGENERATION; NONHUMAN; RAT;

EID: 85032800965     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2017.4197     Document Type: Article

References (44)

1. Tsai CF, Thomas B and Sudlow CL: Epidemiology of stroke and its subtypes in Chinese vs white populations: A systematic review. Neurology 81: 264-272, 2013.
2. Pereira VM, Yilmaz H, Pellaton A, Slater LA, Krings T and Lovblad KO: Current status of mechanical thrombectomy for acute stroke treatment. J Neuroradiol 42: 12-20, 2015.
3. Pierot L, Soize S, Benaissa A and Wakhloo AK: Techniques for endovascular treatment of acute ischemic stroke: From intra-arterial fibrinolytics to stent-retrievers. Stroke 46: 909-914, 2015.
4. Kou X and Chen N: Pharmacological potential of ampelopsin in Rattan tea Food Sci Human Wellness 1: 14-18, 2012.
5. Murakami T, Miyakoshi M, Araho D, Mizutani K, Kambara T, Ikeda T, Chou WH, Inukai M, Takenaka A and Igarashi K: Hepatoprotective activity of tocha, the stems and leaves of Ampelopsis grossedentata, and ampelopsin. Biofactors 21: 175-178, 2004.
6. Tahara S: A journey of twenty-five years through the ecological biochemistry of flavonoids. Biosci Biotechnol Biochem 71: 1387-1404, 2007.
7. Klotter F and Studer A: Total synthesis of resveratrol-based natural products using a palladium-catalyzed decarboxylative arylation and an oxidative Heck reaction. Angew Chem Int Ed Engl 53: 2473-2476, 2014.
8. Pflieger A, Waffo Teguo P, Papastamoulis Y, Chaignepain S, Subra F, Munir S, Delelis O, Lesbats P, Calmels C, Andreola ML, et al: Natural stilbenoids isolated from grapevine exhibiting inhibitory effects against HIV-1 integrase and eukaryote MOS1 transposase in vitro activities. PLoS One 8: e81184, 2013.
9. Qi S, Xin Y, Guo Y, Diao Y, Kou X, Luo L and Yin Z: Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-kB signaling pathways. Int Immunopharmacol 12: 278-287, 2012.
10. Kim JY, Jeong HY, Lee HK, Kim S, Hwang BY, Bae K and Seong YH: Neuroprotection of the leaf and stem of Vitis amurensis and their active compounds against ischemic brain damage in rats and excitotoxicity in cultured neurons. Phytomedicine 19: 150-159, 2012.
11. Zhou Y, Shu F, Liang X, Chang H, Shi L, Peng X, Zhu J and Mi M: Ampelopsin induces cell growth inhibition and apoptosis in breast cancer cells through ROS generation and endoplasmic reticulum stress pathway. PLoS One 9: e89021, 2014.
12. 2-induced apoptosis by ERK and Akt signaling pathways and up-regulation of heme oxygenase-1. Phytother Res 26: 988-994, 2012.
13. Zhang B, Dong S, Cen X, Wang X, Liu X, Zhang H, Zhao X and Wu Y: Ampelopsin sodium exhibits antitumor effects against bladder carcinoma in orthotopic xenograft models. Anticancer Drugs 23: 590-596, 2012.
14. Dung HV, Cuong TD, Chinh NM, Quyen D, Kim JA, Byeon JS, Woo MH, Choi JS and Min BS: Compounds from the aerial parts of Piper bavinum and their anti-cholinesterase activity. Arch Pharm Res 38: 677-682, 2015.
15. β-induced toxicity in PC12 cells. J Nat Prod 77: 213-217, 2014.
16. Lambertsen KL, Biber K and Finsen B: Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 32: 1677-1698, 2012.
17. Shi QJ, Wang H, Liu ZX, Fang SH, Song XM, Lu YB, Zhang WP, Sa XY, Ying HZ and Wei EQ: HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Neuroscience 291: 53-69, 2015.
18. Xing C, Arai K, Lo EH and Hommel M: Pathophysiologic cascades in ischemic stroke. Int J Stroke 7: 378-385, 2012.
19. Turner RC, Dodson SC, Rosen CL and Huber JD: The science of cerebral ischemia and the quest for neuroprotection: Navigating past failure to future success. J Neurosurg 118: 1072-1085, 2013.
20. Kim HH, Oh MH, Park KJ, Heo JH and Lee MW: Anti-inflammatory activity of sulfate-containing phenolic compounds isolated from the leaves of Myrica rubra. Fitoterapia 92: 188-193, 2014.
21. Ku KT, Huang YL, Huang YJ and Chiou WF: Miyabenol A inhibits LPS-induced NO production via IKK/IkappaB inactivation in RAW 264.7 macrophages: Possible involvement of the p38 and PI3K pathways. J Agric Food Chem 56: 8911-8918, 2008.
22. Shi QJ, Xiao L, Zhao B, Zhang XY, Wang XR, Xu DM, Yu SY, Fang SH, Lu YB, Zhang WP, et al: Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats. Brain Res 1484: 57-67, 2012.
23. Chu LS, Wei EQ, Yu GL, Fang SH, Zhou Y, Wang ML and Zhang WP: Pranlukast reduces neutrophil but not macrophage/microglial accumulation in brain after focal cerebral ischemia in mice. Acta Pharmacol Sin 27: 282-288, 2006.
24. Yu GL, Wei EQ, Wang ML, Zhang WP, Zhang SH, Weng JQ, Chu LS, Fang SH, Zhou Y, Chen Z, et al: Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice. Brain Res 1053: 116-125, 2005.
25. Zhang LH and Wei EQ: Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on transient global cerebral ischemia in rats. Acta Pharmacol Sin 24: 1241-1247, 2003.
26. Longa EZ, Weinstein PR, Carlson S and Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91, 1989.
27. Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni G, Muddana N, Saralaya R and Benade V: A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system. J Neurosci Methods 178: 116-119, 2009.
28. Pegg CC, He C, Stroink AR, Kattner KA and Wang CX: Technique for collection of cerebrospinal fluid from the cisterna magna in rat. J Neurosci Methods 187: 8-12, 2010.
29. Yonemori F, Yamaguchi T, Yamada H and Tamura A: Evaluation of a motor deficit after chronic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 18: 1099-1106, 1998.
30. Lin TN, He YY, Wu G, Khan M and Hsu CY: Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 24: 117-121, 1993.
31. Schmued LC and Hopkins KJ: Fluoro-Jade B: A high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 874: 123-130, 2000.
32. Schmidt-Kastner R, Meller D, Bellander BM, Strömberg I, Olson L and Ingvar M: A one-step immunohistochemical method for detection of blood-brain barrier disturbances for immunoglobulins in lesioned rat brain with special reference to false-positive labelling in immunohistochemistry. J Neurosci Methods 46: 121-132, 1993.
33. Tominaga T and Ohnishi ST: Interrelationship of brain edema, motor deficits, and memory impairment in rats exposed to focal ischemia. Stroke 20: 513-518, 1989.
34. Fang SH, Wei EQ, Zhou Y, Wang ML, Zhang WP, Yu GL, Chu LS and Chen Z: Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience 140: 969-979, 2006.
35. Gürer G, Gursoy-Ozdemir Y, Erdemli E, Can A and Dalkara T: Astrocytes are more resistant to focal cerebral ischemia than neurons and die by a delayed necrosis. Brain Pathol 19: 630-641, 2009.
36. Jia F, Yin YH, Gao GY, Wang Y, Cen L and Jiang JY: MMP-9 inhibitor SB-3CT attenuates behavioral impairments and hippocampal loss after traumatic brain injury in rat. J Neurotrauma 31: 1225-1234, 2014.
37. Jiang Z, Watts LT, Huang S, Shen Q, Rodriguez P, Chen C, Zhou C and Duong TQ: The effects of methylene blue on autophagy and apoptosis in MRI-defined normal tissue, ischemic penumbra and ischemic core. PLoS One 10: e0131929, 2015.
38. Gotoh O, Asano T, Koide T and Takakura K: Ischemic brain edema following occlusion of the middle cerebral artery in the rat. I: The time courses of the brain water, sodium and potassium contents and blood-brain barrier permeability to 125I-albumin. Stroke 16: 101-109, 1985.
39. Lv S, Song HL, Zhou Y, Li LX, Cui W, Wang W and Liu P: Tumour necrosis factor-alpha affects blood-brain barrier permeability and tight junction-associated occludin in acute liver failure. Liver Int 30: 1198-1210, 2010.
40. Rodrigues SF and Granger DN: Blood cells and endothelial barrier function. Tissue Barriers 3: e978720, 2015.
41. Willis CL, Brooks TA and Davis TP: Chronic inflammatory pain and the neurovascular unit: A central role for glia in maintaining BBB integrity? Curr Pharm Des 14: 1625-1643, 2008.
42. Candelario-Jalil E: Injury and repair mechanisms in ischemic stroke: Considerations for the development of novel neurotherapeutics. Curr Opin Investig Drugs 10: 644-654, 2009.
43. Kriz J: Inflammation in ischemic brain injury: Timing is important. Crit Rev Neurobiol 18: 145-157, 2006.
44. Jørgensen HS, Nakayama H, Raaschou HO and Olsen TS: Progressive apoplexy. Incidence, risk factors and prognosis-the Copenhagen stroke study. Ugeskr Laeger 157: 3619-3622, 1995 (In Danish).